• Result of Annual General Meeting and operational update

    Read more
  • Further information for shareholders regarding attendance at the Company’s Annual General Meeting on 23 April 2020

    Read more
  • Redx Redmile Loan announcement

    Read more
  • Final Audited Results for the Year Ended 30 September 2019 and operational update

    Read more
  • Redx agrees funding from Redmile Group, LLC & Sofinnova Partners

    Read more
  • Termination of discussions with Yesod Bio-Sciences Limited (“Yesod”)

    Read more
  • Further statement re Rule 2.6 Extension 14 Feb 2020

    Read more
  • Statement re Rule 2.6 Extension

    Read more
  • Result of General Meeting

    Read more
  • Redx Pharma nominates RXC007, a novel, orally active ROCK2 inhibitor as next drug development candidate in fibrosis

    Read more